These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30586485)

  • 1. Adalimumab persistence for inflammatory bowel disease in veteran and insured cohorts.
    Govani SM; Lipson R; Noureldin M; Wiitala W; Higgins PDR; Saini SD; Pugh JA; Velligan DI; Stidham RW; Waljee AK
    Am J Manag Care; 2018 Dec; 24(12):e374-e379. PubMed ID: 30586485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases.
    Govani SM; Noureldin M; Higgins PDR; Heisler M; Saini SD; Stidham RW; Waljee JF; Waljee AK
    Am J Gastroenterol; 2018 Feb; 113(2):276-282. PubMed ID: 29231192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.
    Chen C; Hartzema AG; Xiao H; Wei YJ; Chaudhry N; Ewelukwa O; Glover SC; Zimmermann EM
    Inflamm Bowel Dis; 2019 Jul; 25(8):1417-1427. PubMed ID: 30839057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.
    van der Have M; Oldenburg B; Kaptein AA; Jansen JM; Scheffer RC; van Tuyl BA; van der Meulen-de Jong AE; Pierik M; Siersema PD; van Oijen MG; Fidder HH
    J Crohns Colitis; 2016 May; 10(5):549-55. PubMed ID: 26738757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study.
    Marshall JK; Bessette L; Shear NH; Lebovic G; Glass J; Millson B; Gaetano T; Gazel S; Latour MG; Laliberté MC; Thorne JC
    Clin Ther; 2018 Jun; 40(6):1024-1032. PubMed ID: 29803532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study.
    Srulovici E; Garg V; Ghilai A; Feldman B; Hoshen M; Balicer RD; Skup M; Leventer-Roberts M
    Adv Ther; 2018 May; 35(5):655-665. PubMed ID: 29748914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to subcutaneous biologic treatment for inflammatory bowel disease.
    Ramos L; Ramos-Rodríguez J; Barreda R; Gutiérrez-Nicolás F; Carrillo-Palau M; Alonso-Abreu I; Nazco-Casariego J; Quintero E
    Gastroenterol Hepatol; 2022 May; 45(5):335-341. PubMed ID: 34051312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study.
    Marshall JK; Bessette L; Thorne C; Shear NH; Lebovic G; Gerega SK; Millson B; Oraichi D; Gaetano T; Gazel S; Latour MG; Laliberté MC
    Clin Ther; 2018 Mar; 40(3):415-429.e6. PubMed ID: 29519714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease.
    San EH; Egberts A; van Dijck-van Boetzelaer CWT; West RL; Vasbinder EC
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1089-1096. PubMed ID: 38553558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
    Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
    J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
    Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
    Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
    Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
    JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease.
    Jasurda JS; McCabe RP; Vaughn BP
    Ther Drug Monit; 2021 Oct; 43(5):645-651. PubMed ID: 33346627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
    Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
    J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.